2007 Fiscal Year Final Research Report Summary
Biological features and development/progression of malignant pleural mesothelioma
| Project/Area Number |
18390384
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Hyogo College of Medicine |
|---|
Principal Investigator |
HASEGAWA Seiki Hyogo College of Medicine, FACULTY OF MEDICINE, PROFESSOR (10252438)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TANAKA Fumihiro Hyogo College of Medicine, FACULTY OF MEDICINE, ASSOCIATE PROFESSOR (10283673)
OKUMURA Yoshitomo Hyogo College of Medicine, FACULTY OF MEDICINE, INSTRUCTOR (30388813)
MATSUMOTO Seiji Hyogo College of Medicine, FACULTY OF MEDICINE, INSTRUCTOR (60412011)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | Thoracic surgery / Pleural mesothelioma / Biological features / Tumor progression / Surgery |
|---|
| Research Abstract |
1) Malignant pleural mesothelioma (MPM) is a rare malignant tumor with a poor prognosis; only a few patients can be a candidate for surgical resection, and chemotherapy or radiotherapy is usually ineffective in MPM patients. Thus, to reveal biological features as well as the nature of development and progression of MPM for improvement of the prognosis, the present study has been conducted and the following results were obtained.
2) We routinely conducted mediastinoscopy, contra-lateral thoracoscopy and laparascopy for all potentially resectable MPM patients. As a result, although it had been mentioned that nodal metastases or distant metastases were less common in MPM patients, mediastinal nodal metastases and/or contra-lateral pleural invasion were documented in 36% of patients. In addition, preoperative clinical staging was under-estimated in all 8 patients who achieved complete resection with extrapleural pneumonectomy (EPP).
3) We analyzed biological features of MPM in resected or biopsied MPM tumor specimens, and revealed no novel change specific to MPM; for example, there have been no MPM case with EGFR mutations that is sometimes documented in lung adenocarcinoma and may predict an efficacy of EGFR-tyrosine kinase inhibitors (TKIs). These results suggest that EGER-TKIs are not effective for MPM patients, which is compatible with results in clinical studies.
4) We also examined in vitro sensitivity of MPM cell lines to a various chemotherapeutic agents, and revealed that a schedule-dependent synergistic effect was documented in combination therapy of gemcitabine (GEM) and pemetrexed (MTA), both are key drugs in the treatment of MPM. These results suggest that GEM following MTA can be an optimal chemotherapeutic regimen for MPM.
|
